If this conclusion is correct, it would obviously have important implications for the treatment of all such forms of cancer where COX-2 is expressed in the tumour cells (which should now be easy to find out from biopsy studies), since there is no reason to believe that the delaying effect of COX-2 on disease progression should be restricted to the earliest stages of development of the disease. Here, PTGS2 is linked to neoplasm.